Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD

Research output: Contribution to journalArticle


Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2-3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5-72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P
Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalBone Marrow Transplantation
Issue number1
Publication statusPublished - Jan 1 2017



  • Adult
  • Blood Platelets/chemistry
  • Dry Eye Syndromes/drug therapy
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease/drug therapy
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions/administration & dosage/adverse effects/chemistry
  • Prospective Studies
  • Quality of Life

Cite this